EUVIMEDEUVIMED entdecken
CrossrefInfokarte

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

ONCOLOGY · 2025-08-06 · (3907) · 294-296

DOI: 10.46883/2025.25921046 ↗
AbstractBibliografische Angaben

Abstract

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis; some breast cancer treatments contribute to postdiagnosis weight gain. We evaluated patients with breast cancer who were prescribed a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with follow-up weight data available. Weights were categorized by time from GLP-1 RA initiation; a linear mixed effects model with a random intercept for baseline weight was used to assess mean weight change at each time point. Among 75 patients, the median age was 52 years (range, 27-74), 62 (86%) were postmenopausal, and 59 (79%) had diabetes. Additionally, 68 (91%) patients had stage 0 to III breast cancer, and 62 (84%) had estrogen receptor–positive disease. The median body mass index (BMI) at baseline was 34 (range, 23-50). The mean weight change was –2.9 kg (95% CI, –4.1 to –1.7) at 6 months and –4.2 kg (95% CI, –5.5 to –2.9) at 12 months; mean weight change at 12 months was –5% (95% CI, –6% to –3%). In univariable and multivariable analyses, age, baseline BMI, diabetes, stage, histology, receptor status, menopausal status, and concurrent endocrine therapy use were not significantly associated with 5% or greater weight loss at 12 months. These results support the development of clinical trials to optimize the use and dosing of GLP-1 RAs for weight loss in patients with breast cancer.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →